Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology Inc CHRS
$1.13
▼ -3.42%
($-0.04)
⬇️ Below Yest. Low
Open
$1.17
Prev Close
$1.17
Day Range
$1.13 – $1.19
52W Range
$1.09 – $2.62
Market Cap
$174.59M
P/E (TTM)
1.08
Beta
0.97
EPS (TTM)
$-1.03
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-11-06 |
| Shares Out. | 154,250,000 |
| Website | coherus.com/ ↗ |
| Phone | 13026587581 |
| Employees | 144 |
| Revenue | $14.3M |
| Gross Profit | $10.1M |
| Net Income | -$20.6M |
| Free Cash Flow | -$664.7M |
| Total Assets | $191.2M |
| Total Liabilities | $130.3M |
| Equity | $60.8M |
About Coherus Oncology Inc
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Coherus Oncology Inc is a publicly traded company under the ticker symbol CHRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)